

Research on Heart attacks and heart pump discontinued by sponsor in Pittsburgh and surrounding areas.

Doctors at Allegheny General Hospital planned to participate in a randomized clinical trial to learn if using a FDA-approved Impella CP heart pump in patients with heart shock (a severe heart attack where, the heart is not pumping enough blood to the rest of the body) helped improve survival. On June 4, 2024, the RECOVER IV Trial was discontinued by the sponsor, Abiomed Inc, based on the recommendation from the study's data and safety monitoring board (DSMB), an independent expert committee that monitors safety of patients in the study. The recommendation was made in response to publication of the positive results of a separate study, called DanGer Shock. This study demonstrated that use of Impella CP, heart pump improves survival in patients with heart attack-related shock. Since the discontinuation of the study, no new patients have or will be screened or enrolled in the RECOVER IV Trial. You can find out more information at [website: www.r4study.com/news or 1-888-249-6558].